In EDS ansehen

Long-term trajectories of apolipoprotein A1 and major adverse cardiovascular events and mortality in a community cohort

Gespeichert in:
Bibliographische Detailangaben
Titel: Long-term trajectories of apolipoprotein A1 and major adverse cardiovascular events and mortality in a community cohort
Autoren: Chen, Yang, Chen, Yun-Yu, Chien, Kuo-Liong, Lin, Yenn-Jiang, Chen, Fang-Yi, Hsieh, Yu-Cheng, Lip, Gregory Y H, Chen, Shih-Ann
Quelle: Lipids Health Dis
Lipids in Health and Disease, Vol 24, Iss 1, Pp 1-11 (2025)
Chen, Y, Chen, Y-Y, Chien, K-L, Lin, Y-J, Chen, F-Y, Hsieh, Y-C, Lip, G Y H & Chen, S-A 2025, 'Long-term trajectories of apolipoprotein A1 and major adverse cardiovascular events and mortality in a community cohort', Lipids in Health and Disease, vol. 24, no. 1, 137. https://doi.org/10.1186/s12944-025-02552-3
Verlagsinformationen: Springer Science and Business Media LLC, 2025.
Publikationsjahr: 2025
Schlagwörter: Male, Cholesterol, HDL/blood, Cardiovascular outcomes, RC620-627, Apolipoprotein A-I, Apolipoprotein A-I/blood, Research, Cholesterol, HDL, Middle Aged, All-cause mortality, Cohort Studies, Cardiovascular Diseases, Risk Factors, Major adverse cardiovascular events, Dyslipidemias/blood, Humans, Apolipoprotein A1, Female, Trajectory modeling, Nutritional diseases. Deficiency diseases, Cardiovascular Diseases/mortality, Aged, Dyslipidemias
Beschreibung: Apolipoprotein A1 (ApoA1) is a major component of high-density lipoprotein cholesterol and plays a critical role in reverse cholesterol transport. Dynamic changes in ApoA1 levels may be associated with major adverse cardiovascular events. This study aimed to evaluate the impact of ApoA1 trajectories over three early assessments.Participants in the Chin-Shan Community Cardiovascular Cohort with dyslipidemia and receiving three early ApoA1 assessments were enrolled. Group-based multivariate trajectory modeling was used to classify participants into distinct trajectories after multivariable adjustment. The follow-up duration was from April 1990 to August 2022, and the long-term outcomes of major adverse cardiovascular events (MACE) and death outcomes were evaluated.A total of 1,080 participants were included (median [interquartile range] age 66.14 [57.93-75.04] years, 43.2% males). Participants were classified into four ApoA1 trajectories: Trajectory 1 (low-level persistence pattern); Trajectory 2 (fall-then-rise pattern); Trajectory 3 (rise-then-fall pattern); and Trajectory 4 (elevated stable pattern). The cumulative incidence of MACE was ranked as Trajectory 4 (7.9%)
Publikationsart: Article
Other literature type
Dateibeschreibung: application/pdf
Sprache: English
ISSN: 1476-511X
DOI: 10.1186/s12944-025-02552-3
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40211283
https://doaj.org/article/677d49327c48496482c1fc1a43dd6fc0
Rights: CC BY NC ND
Dokumentencode: edsair.doi.dedup.....a00dccdb31d8b8c134cba021b857a8e5
Datenbank: OpenAIRE
Beschreibung
Abstract:Apolipoprotein A1 (ApoA1) is a major component of high-density lipoprotein cholesterol and plays a critical role in reverse cholesterol transport. Dynamic changes in ApoA1 levels may be associated with major adverse cardiovascular events. This study aimed to evaluate the impact of ApoA1 trajectories over three early assessments.Participants in the Chin-Shan Community Cardiovascular Cohort with dyslipidemia and receiving three early ApoA1 assessments were enrolled. Group-based multivariate trajectory modeling was used to classify participants into distinct trajectories after multivariable adjustment. The follow-up duration was from April 1990 to August 2022, and the long-term outcomes of major adverse cardiovascular events (MACE) and death outcomes were evaluated.A total of 1,080 participants were included (median [interquartile range] age 66.14 [57.93-75.04] years, 43.2% males). Participants were classified into four ApoA1 trajectories: Trajectory 1 (low-level persistence pattern); Trajectory 2 (fall-then-rise pattern); Trajectory 3 (rise-then-fall pattern); and Trajectory 4 (elevated stable pattern). The cumulative incidence of MACE was ranked as Trajectory 4 (7.9%)
ISSN:1476511X
DOI:10.1186/s12944-025-02552-3